ONVO VivoSim Labs Inc.


$ 2.19 $ 0.00 (0 %)    

Friday, 21-Nov-2025 15:54:58 EST
QQQ $ 589.60 $ 4.40 (0.75 %)
DIA $ 462.45 $ 5.05 (1.1 %)
SPY $ 658.47 $ 6.50 (1 %)
TLT $ 89.50 $ 0.27 (0.3 %)
GLD $ 373.70 $ -0.58 (-0.15 %)
$ 2.17
$ 2.09
$ 2.06 x 3
$ 2.14 x 100
$ 2.06 - $ 2.19
$ 1.41 - $ 21.96
25,857
na
na
$ 1.43
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 organovo-has-received-a-notice-of-allowance-for-a-us-patent-titled-engineered-intestinal-tissue-and-uses-thereof

https://patentcenter.uspto.gov/applications/17695538/ifw/docs

 organovo-holdings-issues-2967144-additional-shares-through-warrant-exercises-and-at-the-market-stock-sales-raising-23m-in-gross-proceeds-bringing-total-outstanding-shares-to-20421617

Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company foc...

 why-organovo-onvo-stock-is-skyrocketing

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR prog...

 organovo-holdings-appoints-norman-staskey-as-president-cfo-and-principal-financial-officer-effective-december-30-2024-in-connection-with-resignation-of-tomas-hess---filing

On December 23, 2024, Hess, the Company's former President, Chief Financial Officer and Principal Financial Officer, notifi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION